Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cell therapy shows promise for tough lupus kidney cases

NCT ID NCT05938725

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times

Summary

This early-stage study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The study aims to check safety and whether it can improve kidney function in 6 adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Northwell Health

    Great Neck, New York, 11021, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Stanford University Medical Center

    Palo Alto, California, 94305, United States

  • University of Colorado

    Denver, Colorado, 80045, United States

  • University of Massachusetts Worcester

    Worcester, Massachusetts, 01655, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.